<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191397</url>
  </required_header>
  <id_info>
    <org_study_id>114589</org_study_id>
    <nct_id>NCT02191397</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder</brief_title>
  <official_title>A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (Bupropion XL 300mg Once Daily), Escitalopram Oxalate (Escitalopram, 10mg-20mg Once Daily) in Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-centre study will follow a randomised, double-blind, parallel-group,
      active-controlled design and will evaluate the efficacy, safety and tolerability of bupropion
      extended-release (XL) (300 mg/day) compared with escitalopram (10-20 mg/day) in outpatients
      and inpatients with major depressive disorder (MDD). The total duration of the study will be
      11 weeks consisting of three phases. The screening phase (phase I) will be lasting for 0-14
      days, subjects will be randomised to bupropion XL or escitalopram in a 1:1 ratio for acute
      phase treatment phase (phase II) for 8 weeks. There are 3 dose levels during this acute
      treatment phase. The 3-dose level plan is designed to ensure each drug is titrated according
      to the prescribing information and to reach an optimal clinical dose. Finally patients will
      enter the taper phase (phase III) for up to 1 week to assess and reduce the possible
      withdrawal symptoms.

      In China almost all existing antidepressants are available on the market, but bupropion XL
      has not yet been approved. This Phase III clinical trial will be used for the purpose of
      registering bupropion XL in China.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in Hamilton Depression Rating Scale - 17 (HAMD-17) total score from baseline to end of acute treatment phase (Week 8)</measure>
    <time_frame>Baseline (Week 0) and Week 8</time_frame>
    <description>HAMD-17 is a 17-item questionnaire used to assess the severity of depression and symptom improvement during the treatment. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate based on HAMD-17 total scores</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>HAMD-17 is a 17-item questionnaire used to assess the severity of depression and symptom improvement during the treatment. HAMD-17 has a total score range of 0 (not present) to 52 (severe). Response is defined as decrease in HAMD-17 total score at end-of-treatment relative to baseline by at least 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate based on HAMD-17 total scores</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Remission is defined as HAMD-17 total score at end-of-treatment &lt;=7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained response rate based on HAMD-17 total scores</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Sustained response is defined as response at end-of-treatment and an earlier visit and decrease in HAMD-17 total score without missing score at all visits between these two visits by at least 40%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained remission rate based on HAMD-17 total scores</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Sustained remission is defined as remission at end-of-treatment and an earlier visit and HAMD-17 total score without missing score at all visits between these two visits &lt;= 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at weeks 1, 2, 4, 6, 8</measure>
    <time_frame>Baseline (Week 0), Weeks 1, 2, 4, 6 and 8</time_frame>
    <description>MADRS is a 10-point rating scale used to assess the efficacy of antidepressant treatment. Each item is scored on a scale of 0-6, with a total score range of 0-60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HAMD-17 Item 1 depressed mood item score at weeks 1, 2, 4, 6, 8</measure>
    <time_frame>Baseline (Week 0), Weeks 1, 2, 4, 6 and 8</time_frame>
    <description>HAMD-17 Item 1 depressed mood item assesses feelings of sadness, hopelessness, helplessness, and worthlessness on a scale of 0 to 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HAMD-17 anxiety/somatization subscale score at Weeks 1, 2, 4, 6, 8</measure>
    <time_frame>Baseline (Week 0), Weeks 1, 2, 4, 6 and 8</time_frame>
    <description>Anxiety/somatization subscale score is the sum of scores of items 10, 11, 12, 13, 15 and 17.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HAMD-17 retardation subscale score (sum of scores of items 1, 7, 8 and 14) at Weeks 1, 2, 4, 6, 8</measure>
    <time_frame>Baseline (Week 0), Weeks 1, 2, 4, 6 and 8</time_frame>
    <description>Retardation subscale score is the sum of scores of items 1, 7, 8 and 14 where Item 1 is depressed mood, 7-work and activities, 8-retardation-psychomotor and 14-genital symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HAMD-17 sleep disorder subscale at Weeks 1, 2, 4, 6, 8</measure>
    <time_frame>Baseline (Week 0), Weeks 1, 2, 4, 6 and 8</time_frame>
    <description>Sleep disorder subscale score is the sum of scores of items 4, 5 and 6 where Item 4 is insomnia early, 5-insomina middle and 6- insomnia late</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) score at Weeks 1, 2, 4, 6, 8.</measure>
    <time_frame>Baseline (Week 0), Weeks 1, 2, 4, 6 and 8</time_frame>
    <description>CGI-S records the severity of illness at specific time points, with a range of responses from 1 (normal) to 7 (Among the most extremely ill patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with a CGI-I score of 1 (&quot;very much improved&quot;) or 2 (&quot;much improved&quot;) at Weeks 1, 2, 4, 6, 8</measure>
    <time_frame>Baseline (Week 0), Weeks 1, 2, 4, 6 and 8</time_frame>
    <description>Clinical Global Impression Global Improvement (CGI-I) rating, indicate assessment of the subject's total improvement or worsening compared to the subject's condition at the Baseline Visit, whether or not the improvement or worsening is thought to be treatment related.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subject with Adverse events</measure>
    <time_frame>Up to Week 10</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vitals sign</measure>
    <time_frame>Up to Week 10</time_frame>
    <description>Vital sign measurements includes systolic and diastolic blood pressure and pulse rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in -lead electrocardiogram (ECG)</measure>
    <time_frame>Up to Week 10</time_frame>
    <description>The 12-lead ECG will be performed in accordance with the study procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinical laboratory test</measure>
    <time_frame>Up to Week 10</time_frame>
    <description>Clinical laboratory parameters include: Hematology, clinical chemistry and urinalysis parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in changes in sexual functioning questionnaire (CSFQ)</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>CSFQ is a 14-item subject-rated scale assessing changes in sexual activity and functioning; structured interview/questionnaire, designed to measure medication related changes in sexual functioning. 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. Total score: obtained across all 5 dimensions, ranges from 14 to 70.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">529</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Bupropion Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.</description>
    <arm_group_label>Bupropion Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion Matching Placebo</intervention_name>
    <description>Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding</description>
    <arm_group_label>Escitalopram Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.</description>
    <arm_group_label>Escitalopram Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram Matching Placebo</intervention_name>
    <description>Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding</description>
    <arm_group_label>Bupropion Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have the ability to effectively communicate with investigator, complete
             study related documents, comprehend the key components of the consent form and must
             provide written informed consent to participate in the study prior to any
             study-specific assessments or procedures.

          -  An in- patient or out-patient (male or female) and aged &gt;=18 years.

          -  A diagnosis of MDD, nonpsychotic, single episode or recurrent, Diagnostic and
             Statistical Manual of Mental Disorders-IV (DSM-IV) (296.2/296.3), utilizing the Mini
             International Neuropsychiatric Interview (MINI).

          -  Established MDD diagnosis with a duration of at least 4 weeks.

          -  HAMD-17 total score of &gt;=20 and a CGI-S score of &gt;=4 at both the Screening Visit and
             the Baseline Visit.

          -  Subject must be in general good health and be considered clinically appropriate for
             therapy with bupropion or escitalopram, based upon the investigator's overall clinical
             evaluation.

          -  Female patients of child-bearing potential only: patients must not be lactating and
             must test negative for pregnancy at screening and agree to use a medically accepted
             method of birth control during the study.

          -  Liver function tests: alanine aminotransferase (ALT) &lt;2x upper limit of normal (ULN);
             alkaline phosphatase and bilirubin &lt;=1.5xULN (isolated bilirubin &gt;1.5 x ULN is
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).

          -  Corrected QT (QTc) criteriaï¼š QTc &lt;450 milliseconds (msec) or QTc &lt;480msec for patients
             with bundle branch block. The QTc is the QT interval corrected for heart rate
             according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or machine
             or manual overread. For subject eligibility and withdrawal, QTcF will be used. For
             purpose of data analysis, QTcF will be used. The QTc should be based on single or
             averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief
             recording period.

        Exclusion Criteria:

          -  Has been diagnosed or received treatment for a primary Axis I disorder with the
             exception of MDD (including current or past diagnosis of anorexia nervosa or bulimia).
             Additionally, subjects diagnosed with dysthymic disorder within the past 2 years will
             be excluded.

          -  Current DSM-IV Axis II diagnosis that suggests non-compliance with the protocol.

          -  A subject who, in the assessment with the Columbia Suicide Severity Rating Scale
             (C-SSRS) and investigator's judgment, poses suicidal risk, or had suicide attempt or
             behavior within 6 months prior to the Screening Visit.

          -  Current or past history of seizure disorder or brain injury (traumatic or disease
             related); or any condition which, in the opinion of the investigator, predisposed to
             seizure; subjects treated with other medications or treatment regimes that lower
             seizure threshold. Note: single childhood febrile seizure is not exclusionary.

          -  In the Investigator's judgment, presence of clinically significant laboratory test
             results (including ECG, hematology, chemistry and urine), or the conditions which
             render patients unsuitable for the study (such as serious cardiovascular disease,
             uncontrolled hypertension, liver or renal insufficiency) and pose a safety concern or
             interfere with the accurate safety and efficacy assessments. Subjects with
             co-morbidities (such as diabetes, hypertension, hypothyroid, chronic respiratory
             diseases or other physical illness) were eligible if their condition had been stable
             for at least three months and they had been receiving standard therapy for the
             condition for at least three months.

          -  Unstable liver disease (as defined by the presence of ascites, encephalopathy,
             coagulopathy, hypoalbuminaemia, oesophageal or gastric varices or persistent
             jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's
             syndrome or asymptomatic gallstones)

          -  Frequent and/or severe allergic reactions with multiple medications, or history of a
             medically significant adverse effect (including allergic reaction) from any
             medications or compounds in the study.

          -  Use of prohibited psychotropic drugs not allowed within seven days (14 days for
             monoamine oxidase inhibitors (MAOIs), 30 days for fluoxetine) prior to the Baseline
             Visit.

          -  Subjects who have attended any studies investigating bupropion or escitalopram 6
             months prior to this study, or use of bupropion or escitalopram in the last 4 weeks.

          -  Participation in other clinical studies unrelated to the current illness within 30
             days or participation in other clinical studies related to the current illness within
             3 months.

          -  Initiation of systematic psychotherapy within three months prior to the Screening
             Visit, or plans to initiate systematic psychotherapy during the study.

          -  Received electroconvulsive therapy (ECT), modify electroconvulsive therapy (MECT),
             transcranial magnetic stimulation (TMS), or other physical therapy within the 6 months
             prior to the Screening Visit.

          -  Previous failure of bupropion or escitalopram treatment with adequate courses and
             doses.

          -  Previous or present failure of two different classes of antidepressants treatment with
             adequate courses (e.g. maximum labelled doses for &gt;=4 weeks).

          -  History of substance abuse (alcohol or drugs) or substance dependence within 12 months
             (as defined in the DSM-IV).

          -  Other conditions which, in the Investigator's judgment, render patients unsuitable for
             the clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changsha</city>
        <state>Henan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Xian</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Escitalopram</keyword>
  <keyword>Major depressive disorder</keyword>
  <keyword>Non-inferiority</keyword>
  <keyword>Bupropion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzocaine</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 9, 2017</submitted>
    <submission_canceled>May 10, 2018</submission_canceled>
    <submitted>May 10, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

